Clinically important pharmacokinetic drug-drug interactions: Role of cytochrome P450 enzymes

Journal of Clinical Pharmacy and Therapeutics

Volumn 23, Issue 6, 1998, Pages 403-416

  Tanaka, E ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CYCLOSPORIN; CYTOCHROME P450; ENZYME; ERYTHROMYCIN; OMEPRAZOLE; RIFAMPICIN; TERFENADINE;

ALCOHOL CONSUMPTION; DRUG INTERACTION; ENVIRONMENTAL FACTOR; ENZYME INDUCTION; ENZYME INHIBITION; FRUIT JUICE; LIVER; PHARMACOKINETICS; REVIEW; SMOKING;

EID: 0032456884     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.1998.00086.x     Document Type: Review

References (148)

1. Guengerich FP. (1992) Characterization of human cytochrome P450 enzymes. FASEB Journal, 6(2), 745-748.
2. Nelson DR, Kamataki T, Waxman DJ, et al. (1993) The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA and Cell Biology, 12(1), 1-51.
3. Nebert DW, Nelson DR, Coon MJ, et al. (1991) The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA and Cell Biology, 10(1), 1-14.
4. Nakamura K, Goto F, Ray WA, et al. (1985) Interethinic differences in genetic polymorphism of debrisoquin and mepheytoin hydroxylation between Japanese and Caucasian population. Clinical Pharmacology and Therapeutics, 38, 402-408.
5. Wilkinson GR, Guengerich FP, Branch RA. (1989) Genetic polymorphism of S-mepheytoin hydroxylation. Pharmacology and Therapeutics, 43, 53-76.
6. Bertilsson L, Lou YQ, Du YL, et al. (1992) Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mepheytoin. Clinical Pharmacology and Therapeutics, 51, 388-397.
7. Wrighton SA, Stevens JC, Becker GW, Vanden-Branden. (1993) Isolation and characterization of human liver cytochrome P450:2C19: correlation between 2C19 and S-mepheytoin hydrpxylation. Archives of Biochemistry and Biophysics, 306, 240-245.
8. Mehgoub A, Dring LG, Idle JR, Lancaster R, Smith RL. (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet, 2, 584-586.
9. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. European Journal of Clinical Pharmacology, 16, 183-187.
10. Brøsen K, Gram LF. (1989) Clinical significance of the sparteine/debrisoquine oxidation polymorphism. European Journal of Clinical Pharmacology, 36, 537-547.
11. Meyer UA, Skoda RC, Zanger UM. (1990) The genetic polymorphism of debrisoquine/sparteine metabolism: molecular mechanisms. Pharmacology and Therapeutics, 46, 297-308.
12. Eichelbaum M, Gross. (1990) The genetic polymorphism of debrisoquine/sparteine metabolism: clinical aspects. Pharmacology and Therapeutics, 46, 377-394.
13. Lennard MS. (1990) Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal. Pharmacology and Toxicology, 67, 273-283.
14. Gonzalez FK, Meyer UA. (1991) Molecular genetics of the debrisoquine/sparteine metabolism. Clinical Pharmacology and Therapeutics, 50, 233-238.
15. Okuda H, Nishiyama T, Ogura K, et al. (1997) Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metabolism and Disposition, 25, 270-273.
16. Desgranges C, Razaka G, De Clercq E, et al. (1986) Effect of (E) -5-(2-bromovinyl) uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. Cancer Research, 46, 1094-1101.
17. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr. (1990) Torsades de pointes occurring in association with terfenadine use. JAMA, 264, 2788-2790.
18. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. (1993) Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA, 269, 1513-1518.
19. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr. (1992) Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clinical Pharmacology and Therapeutics, 52, 231-238.
20. Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen P. (1993) Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. European Journal of Clinical Pharmacology, 45, 191-193.
21. Mattila MJ. (1990) Alcohol and drug interactions. Annals of Medicine, 22, 363-369.
22. Humphries TJ. (1991) Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole. Digestive Diseases and Sciences, 36, C1665-C1669.
23. Andersson T. (1991) Omeprazole drug interaction studies. Clinical Pharmacokinetics, 21, 195-212.
24. Periti P, Mazzei T, Mini E, Novelli A. (1992) Pharmacokinetic drug interactions of macrolides. Clinical Pharmacokinetics, 23, 106-131.
25. Gillum JG, Israel DS, Polk RE. (1993) Pharmacokinetic drug interactions with antimicrobial agents. Clinical Pharmacokinetics, 25, 450-482.
26. Maurer PM, Bartkowski RR. (1993) Drug interactions of clinical significance with opioid analgesics. Drug Safety, 8, 30-48.
27. Finley PR. (1994) Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions. Annals of Pharmacotherapy, 28, 1359-1369.
28. Grange JM, Winstanley PA, Davies PD. (1994) Clinically significant drug interactions with antituberculosis agents. Drug Safety, 11, 242-251.
29. DeVane CL. (1994) Pharmacogenetics and drug metabolism of newer antidepressant agents. Journal of Clinical Psychiatry, 55(Suppl.), 38-47.
30. Shen WW. (1995) Cytochrome P450 monooxygenases and interactions of psychotropic drugs: a five-year update. Journal of Psychiatry in Medicine, 25, 277-290.
31. Kivisto KT, Kroemer HK, Eichelbaum M. (1995) The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. British Journal of Clinical Pharmacology, 40, 523-530.
32. Levy RH. (1995) Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia, 36(Suppl. 5), S8-S13.
33. Ketter TA, Flockhart DA, Post RM, et al. (1995) The emerging role of cytochrome P450, 3A in psychopharmacology. Journal of Clinical Psychopharmacology, 15, 387-398.
34. von Rosensteil NA, Adam D. (1995) Macrolide antibacterials. Drug interactions of clinical significance. Drug Safety, 13, 105-122.
35. Ciummo PE, Katz NL. (1995) Interactions and drug-metabolizing enzymes. American Pharmacy, 35, 41-51.
36. Slaughter RL, Edwards DJ. (1995) Recent advances: the cytochrome P450 enzymes. Annals of Pharmacotherapy, 29, 619-624.
37. Brosen K. (1995) Drug interactions and the cytochrome P450: system. The Role of Cytochrome P450 1A2 Clinical Pharmacokinetics, 29(Suppl. 1), 20-25.
38. Ereshefsky L, Riesenman C, Lam YW. (1995) Anti-depressant drug interactions and the cytochrome P450: system. The Role of Cytochrome P450 2D6. Clinical Pharmacokinetics, 29(Suppl. 1), 10-18; discussion 18-19.
39. Flockhart DA. (1995) Drug interactions and the cytochrome P450: system. The role of cytochrome P450 2C19. Clinical Pharmacokinetics, 29(Suppl. 1), 45-52.
40. von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI. (1995) Metabolism of drugs by cytochrome P450, 3A isoforms. Implications for drug interactions in psychopharmacology. Clinical Pharmacokinetics, 29(Suppl. 1), 33-43.
41. Harder S, Thurmann P. (1996) Clinically important drug interactions with anticoagulants. An update. Clinical Pharmacokinetics, 30, 416-444.
42. Borcherding SM, Stevens R, Nicholas RA, Corley CR, Self T. (1996) Quinolones: a practical review of clinical uses, dosing considerations, and drug interactions. Journal of Family Practice, 42, 69-78.
43. Taburet AM, Singlas E. (1996) Drug interactions with antiviral drugs. Clinical Pharmacokinetics, 30, 385-401.
44. Ereshefsky L. (1996) Pharmacokinetics and drug interactions: update for new antipsychotics. Journal of Clinical Psychiatry, 57(Suppl. 11), 12-25.
45. Ereshefsky L, Riesenman C, Lam YW. (1996) Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system. Journal of Clinical Psychiatry, 57(Suppl. 8), 17-24.
46. Nemeroff CB, DeVane CL, Pollock BG. (1996) Newer antidepressants and the cytochrome P450 system. American Journal of Psychiatry, 135, 311-320.
47. Watkins VS, Polk RE, Stotka JL. (1997) Drug interactions of macrolides: emphasis on dirithromycin. Annals of Pharmacotherapy, 31, 349-356.
48. Paterson DL, Singh N. (1997) Interactions between tacrolimus and antimicrobial agents. Clinical Infectious Diseases, 25, 1430-1440.
49. Virani A, Mailis A, Shapiro LE, Shear NH. (1997) Drug interactions in human neuropathic pain pharmacotherapy. Pain, 73, 3-13.
50. Mitchell PB. (1997) Drug interactions of clinical significance with selective serotonin reuptake inhibitors. Drug Safety, 17, 390-406.
51. Mignat C. (1997) Clinically significant drug interactions with new immunosuppressive agents. Drug Safety, 16, 267-278.
52. Singer MI, Shapiro LE, Shear NH. (1997) Cytochrome P-450, 3A: interactions with dermatologic therapies. Journal of the American Academy of Dermatology, 37, 765-771.
53. Unge P, Andersson T. (1997) Drug interactions with proton pump inhibitors. Drug Safety, 16, 171-179.
54. Fraser AG. (1997) Pharmacokinetic interactions between alcohol and other drugs. Clinical Pharmacokinetics, 33, 79-90.
55. Sproule BA, Naranjo CA, Brenmer KE, Hassan PC. (1997) Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clinical Pharmacokinetics, 33, 454-471.
56. Guengerich FP. (1997) Role of cytochrome P450 enzymes in drug-drug interactions. Advances in Pharmacology, 43, 7-35.
57. Albengres E, Le Louet H, Tillement JP. (1998) Systemic antifungal agents. Drug interactions of clinical significance. Drug Safety, 18, 83-97.
58. Cupp MJ, Tracy TS. (1998) Cytochrome P450: new nomenclature and clinical implications. American Family Physician, 57, 107-116.
59. Baker GB, Fang J, Sinha S, Coutts RT. (1998) Metabolic drug interactions with selective serotonin reuptake inhibitor (SSRI) antidepressants. Neuroscience and Biobehavioral Reviews, 22, 325-333.
60. McLeod HL. (1998) Clinically relevant drug-drug interactions in oncology. British Journal of Clinical Pharmacology, 45, 539-544.
61. Miners JO, Birkett DJ. (1998) Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. British Journal of Clinical Pharmacology, 45, 525-538.
62. Negro RD. (1998) Pharmacokinetic drug interactions with anti-ulcer drugs. Clinical Pharmacokinetics, 35, 135-150.
63. Michalets EL. (1998) Update: clinically significant cytochrome P450 drug interactions. Pharmacotherapy, 18, 84-112.
64. Dossing M, Pilsgaard H, Rasmussen B, Poulsen HE. (1983) Time course of phenobarbital and cimetidine mediated changes in hepatic drug metabolism. European Journal of Clinical Pharmacology, 25, 215-222.
65. von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI. (1998) In vitro approaches to predicting drug interactions in vivo. Biochemical Pharmacology, 55, 113-122.
66. Guengerich FP, Gillam EM, Shimada T. (1996) New applications of bacterial systems to problems in toxicology. Critical Reviews in Toxicology, 26, 551-583.
67. Markowitz JS, Wells BG, Carson WH. (1995) Interactions between antipsychotic and antihypertensive drugs. Annals of Pharmacotherapy, 29, 603-609.
68. Vanden Bossche H, Koymans L, Moereels H. (1995) P450 inhibitors of use in medical treatment: focus on mechanisms of action. Pharmacology and Therapeutics, 67, 79-100.
69. Murray M. (1997) Drug-mediated inactivation of cytochrome P450. Clinical and Experimental Pharmacology and Physiology, 24, 465-470.
70. Wagner F, Kalusche D, Trenk D, Jahnchen E, Roskamm H. (1987) Drug interaction between propafenone and metoprolol. British Journal of Clinical Pharmacology, 24, 213-220.
71. Markowitz JS, Wells BG, Carson WH. (1995) Interactions between antipsychotic and antihypertensive drugs. Annals of Pharmacotherapy, 29, 603-609.
72. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. (1994) Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. Journal of Clinical Psychopharmacology, 14, 90-98.
73. Zomorodi K, Houston JB. (1995) Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies. Pharmaceutical Research, 12, 1642-1646.
74. Meyer UA. (1996) Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. Yale Journal of Biology and Medicine, 69, 203-209.
75. Zomorodi K, Houston JB. (1996) Diazepam-omeprazole inhibition interaction: an in vitro investigation using human liver microsomes. British Journal of Clinical Pharmacology, 42, 157-162.
76. Jones TE, Morris RG. (1996) Diltiazem does not always increase blood cyclosporin concentration. British Journal of Clinical Pharmacology, 42, 642-644.
77. Campana C, Regazzi MB, Buggia I, Molinaro M. (1996) Clinically significant drug interactions with cyclosporin. Clinical Pharmacokinetics, 30, 141-179.
78. Jones TE, Morris RG, Mathew TH. (1997) Diltiazem-cyclosporin pharmacokinetic interaction: dose-response relationship. British Journal of Clinical Pharmacology, 44, 499-504.
79. Nahata M. (1996) Drug interactions with azithromycin and the macrolides: an overview. Journal of Antimicrobial Chemotherapy, 37(Suppl. C), 133-142.
80. Gurevitz SL. (1997) Erythromycin: drug interactions. Journal of Dental Hygiene, 71, 159-161.
81. Stafstrom CE, Nohria V, Loganbill H, Nahouraii R, Boustany RM, DeLong GR. (1995) Erythromycin-induced carbamazepine toxicity: a continuing problem. Archives of Pediatrics and Adolescent Medicine, 149, 99-101.
82. Levy RH. (1995) Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia, 36(Suppl. 5), S8-S13.
83. Mota CR, Carvalho C, Mota C, Ferreira P, Vilarinho A, Pereira E. (1996) Severe carbamazepine toxicity induced by concurrent erythromycin therapy. European Journal of Pediatrics, 155, 345.
84. Lown KS, Thummel KE, Benedict PE, et al. (1995) The erythromycin breath test predicts the clearance of midazolam. Clinical Pharmacology and Therapeutics, 57, 16-24.
85. Zimmermann T, Yeates RA, Laufen H, Scharpf F, Leitold M, Wildfeuer A. (1996) Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam. Arztneimittel-Forschung, 46, 213-217.
86. Yeates RA, Laufen H, Zimmermann T, Schumacher T. (1997) Pharmacokinetic and pharmacodynamic interaction study between midazolam and the macrolide antibiotics, erythromycin, clarithromycin, and the azalide azithromycin. International Journal of Clinical Pharmacology and Therapeutics, 35, 577-579.
87. Campana C, Regazzi MB, Buggia I, Molinaro M. (1996) Clinically significant drug interactions with cyclosporin. An update. Clinical Pharmacokinetics, 30, 141-179.
88. Rodrigues AD, Mulford DJ, Lee RD, et al. (1995) In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P450:3A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices. Drug Metabolism and Disposition, 23, 765-775.
89. Ling KH, Leeson GA, Burmaster SD, Hook RH, Reith MK, Cheng LK. (1995) Metabolism of terfenadine associated with CYP3A (4) activity in human hepatic microsomes. Drug Metabolism and Disposition, 23, 631-636.
90. Somogyi A, Gugler A. (1982) Drug interactions with cimetidine. Clinical Pharmacokinetics, 7, 23-41.
91. Somogyi A, Muirhead M. (1987) Pharmacokinetic interactions of cimetidine 1987. Clinical Pharmacokinetics, 12, 321-366.
92. Maurice M, Pichard L, Daujat M, et al. (1992) Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB Journal, 6, 752-758.
93. Ortiz de Montellano PR, Kunze KL, Yost GS, Mico BA. (1979) Self-catalyzed destruction of cytochrome P-450: covalent binding of ethynyl sterols to prosthetic heme. Proceedings of the National Academy of Sciences of the United States of America, 76, 746-749.
94. Walubo A, Aboo A. (1995) Phenytoin toxicity due to concomitant antituberculosis therapy. South African Medical Journal, 85, 1175-1176.
95. Back DJ, Orme ML. (1990) Pharmacokinetic drug interactions with oral contraceptives. Clinical Pharmacokinetics, 18, 472-484.
96. Guengerich FP. (1990) Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chemical Research in Toxicology, 3, 363-371.
97. Gan LS, Acebo AL, Alworth WL. (1984) 1-Ethynylpyrene, a suicide inhibitor of cytochrome P-450 dependent benzo[a]pyrene hydroxylase activity in liver microsomes. Biochemistry, 23, 3827-3836.
98. Venkatesan K. (1992) Pharmacokinetic drug interactions with rifampicin. Clinical Pharmacokinetics, 22, 47-65.
99. Lee KH, Shin JG, Chong WS, et al. (1993) Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin. European Journal of Clinical Pharmacology, 45, 287-289.87.
100. Burger DM, Meenhorst PL, Koks CH, Beijnen JH. (1993) Pharmacokinetic interaction between rifampin and zidovudine. Antimicrobial Agents and Chemotherapy, 37, 1426-1431.
101. Grange JM, Winstanley PA, Davies PD. (1994) Clinically significant drug interactions with antituberculosis agents. Drug Safety, 11, 242-251.
102. Koselj M, Bren A, Kandus A, Kovac D. (1994) Drug interactions between cyclosporine and rifampicin, erythromycin, and azoles in kidney recipients with opportunistic infections. Transplantation Proceedings, 26, 2823-2824.
103. Holtbecker N, Fromm MF, Kroemer HK, Ohnhaus EE, Heidemann H. (1996) The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. Drug Metabolism and Disposition, 24, 1121-1123.
104. Li AP, Reith MK, Rasmussen A, et al. (1997) Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. Chemico-Biological Interactions, 107, 17-30.
105. Fromm MF, Eckhardt K, Li S, et al. (1997) Loss of analgesic effect of morphine due to coadministration of rifampin. Pain, 72, 261-267.
106. Fromm MF, Busse D, Kroemer HK, Eichelbaum M. (1997) Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology, 24, 796-801.
107. Fleishaker JC, Pearson LK, Peters GR. (1996) Gender does not affect the degree of duction of tirilazad clearance by phenobarbital. European Journal of Clinical Pharmacology, 50, 139-145.
108. Rambeck B, Specht U, Wolf P. (1996) Pharmacokinetic interactions of the new antiepileptic drugs. Clinical Pharmacokinetics, 31, 309-324.
109. Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ. (1996) Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia, 37, 253-257.
110. Cropp JS, Bussey HI. (1997) A review of enzyme induction of warfarin metabolism with recommendations for patient management. Pharmacotherapy, 17, 917-928.
111. Jusko WJ. (1978) Role of tobacco smoking in pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics, 6, 7-39.
112. Schein JR. (1995) Cigarette smoking and clinically significant drug interactions. Annals of Pharmacotherapy, 29, 1139-1148.
113. Morel F, Beaune PH, Ratanasavanh D, et al. (1990) Expression of cytochrome P-450 enzymes in cultured human hepatocytes. European Journal of Biochemistry, 191, 437-444.
114. Perrot N, Nalpas B, Yang CS, Beaune PH. (1989) Modulation of cytochrome P450 isozymes in human liver, by ethanol and drug intake. European Journal of Clinical Investigation, 19, 549-555.
115. Kim RB, O'Shea D, Wilkinson GR. (1994) Relationship in healthy subjects between CYP2E1 genetic polymorphisms and the 6-hydroxylation of chlorzoxazone: a putative measure of CYP2E1 activity. Pharmacogenetics, 4, 162-165.
116. Pelkonen O, Pasanen M, Kuha H, et al. (1986) The effect of cigarette smoking on 7-ethoxyresorufin O-deethylase and other monooxygenase activities in human liver: analyses with monoclonal antibodies. British Journal of Clinical Pharmacology, 22, 125-134.
117. Sesardic D, Boobis AR, Edwards RJ, Davies DS. (1988) A form of cytochrome P450: in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. British Journal of Clinical Pharmacology, C, 26, 363-372.
118. Yun CH, Okerholm RA, Guengerich FP. (1993) Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450, 3A (4) in N-dealkylation and C-hydroxylation. Drug Metabolism and Disposition, 21, 403-409.
119. Rodrigues AD, Mulford DJ, Lee RD, et al. (1995) In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P450:3A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices. Drug Metabolism and Disposition, 23, 765-775.
120. Knodell RG, Browne DG, Gwozdz GP, Brian WR, Guengerich FP. (1991) Differential inhibition of individual human liver cytochromes P-450 by cimetidine. Gastroenterology, 101, 1680-1691.
121. Jou MJ, Huang SC, Kiang FM, Lai MY, Chao PD. (1977) Comparison of the effects of cimetidine and ranitidine on the pharmacokinetics of disopyramide in man. Journal of Pharmacy and Pharmacology, 49, 1072-1075.
122. Tanaka E, Nakamura K. (1988) Effects of H2-receptor antagonists on ethanol metabolism in Japanese volunteers. British Journal of Clinical Pharmacology, 26, 96-99.
123. Bailey DG, Arnold JM, Spence JD. (1994) Grapefruit juice and drugs. How significant is the interaction? Clinical Pharmacokinetics, 26, 91-98.
124. Ameer B, Weintraub RA. (1997) Drug interactions with grapefruit juice. Clinical Pharmacokinetics, 33, 103-121.
125. Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ. (1995) Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clinical Pharmacology and Therapeutics, 58, 127-131.
126. Bailey DG, Spence JD, Edgar B, Bayliff CD, Arnold JM. (1989) Ethanol enhances the hemodynamic effects of felodipine. Clinical and Investigative Medicine - Medecine Clinique et Experimentale, 12, 357-362.
127. Gugler R, Jensen JC. (1985) Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology, 89, 1235-1241.
128. Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P. (1990) Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clinical Pharmacology and Therapeutics, 47, 79-85.
129. Andersson T. (1996) Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clinical Pharmacokinetics, 31, 9-28.
130. Kivisto KT, Neuvonen PJ, Klotz U. (1994) Inhibition of terfenadine metabolism. Pharmacokinetic and pharmacodynamic consequences. Clinical Pharmacokinetics, 27, 1-5.
131. Godin JR, Sketris IS, Belitsky P. (1986) Erythromycin-cyclosporin interaction. Drug Intelligence and Clinical Pharmacy, 20, 504-505.
132. Brian WR, Sari MA, Iwasaki M, Shimada T, Kaminsky LS, Guengerich FP. (1990) Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae. Biochemistry, 29, 11280-11292.
133. Gillam EM, Guo Z, Ueng YF, et al. (1995) Expression of cytochrome P450: 3A5 in Escherichia coli: effects of 5 modification, purification, spectral characterization, reconstitution conditions, and catalytic activities. Archives of Biochemistry and Biophysics, 317, 374-384.
134. Kronbach T, Fischer V, Meyer UA. (1988) Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with otherdrugs. Clinical Pharmacology and Therapeutics, 43, 630-635.
135. Combalbert J, Fabre I, Fabre G, et al. (1989) Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metabolism and Disposition, 17, 197-207.
136. Aoyama T, Yamano S, Waxman DJ, et al. (1989) Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. Journal of Biological Chemistry, 264, 10388-10395.
137. Lucey MR, Kolars JC, Merion RM, Campbell DA, Aldrich M, Watkins PB. (1990) Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA. Lancet, 335, 11-15.
138. Breckenridge A. (1992) Clinical significance ofteractions with antifungal agents. British Journal of Dermatology, 126(Suppl. 39), 19-22.
139. Murphy R, Swartz R, Watkins PB. (1990) Severe acetaminophen toxicity in a patient receiving isoniazid. Annals of Internal Medicine, 113, 799-800.
140. Guengerich FP, Brian WR, Iwasaki M, Sari MA, Baarnhielm C, Berntsson P. (1991) Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. Journal of Medicinal Chemistry, 34, 1838-1844.
141. Hunt SN, Jusko WJ, Yurchak AM. (1976) Effect of smoking on theophylline disposition. Clinical Pharmacology and Therapeutics, 19(1), 546-551.
142. Sesardic D, Boobis AR, Edwards RJ, Davies DS. (1988) A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. British Journal of Clinical Pharmacology, 26, 363-372.
143. Lieber CS, Lasker JM, Alderman J, Leo MA. (1987) The microsomal ethanol oxidizing system and its interaction with other drugs, carcinogens, and vitamins. Annals of the New York Academy of Sciences, 492, 11-24.
144. Lieber CS. (1994) Mechanisms of ethanol-drug-nutrition interactions. Journal of Toxicology - Clinical Toxicology, 32, 631-681.
145. Lieber CS. (1994) Susceptibility to alcohol-related liver injury. Alcohol and Alcoholism, Suppl.2, 315-326.
146. Kitson KE. (1996) Ethanol and acetaldehyde metabolism: past, present and future. Alcoholism, Clinical and Experimental Research, 20(Suppl.8), 82A-92A.
147. Asai H, Imaoka S. (1996) Microsomal ethanol oxidizing system activity by human hepatic cytochrome P450s. Journal of Pharmacology and Experimental Therapeutics, 277, 1004-1009.
148. Song BJ. (1996) Ethanol-inducible cytochrome P450: (CYP2E1): biochemistry, molecular biology and clinical relevance. 1996 Up-Date. Alcoholism, Clinical and Experimental Research, 20(Suppl.8), 138A-146A.